-
Company Insights
Innovation and Patenting activity of Frequency Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Frequency Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Consumer Insights
NewSpain Apparel Consumer Insights – Who Shops, What do they Shop, How do they Shop and Why do they Shop
This report provides detailed consumer insights into Spanish apparel market. It centers on consumer sentiment, categories purchased, channel usage, motivations for purchasing, purchase frequency and the most popular global brands. Spain’s inflation rate is softening, slowing to 3.8% in December 2023 from 8.3% in 2022, driving less than half of consumers to expect the economy to get worse in the next six months. In 2023, 81.4% of apparel shoppers bought items instore, while 61.1% purchased online, as consumers favoured being...
-
Product Insights
NewLikelihood of Approval Analysis for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
Overview How likely is it that the drugs in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)...
-
Product Insights
NewLikelihood of Approval Analysis for Streptococcal Pneumonia
Overview How likely is it that the drugs in Streptococcal Pneumonia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Streptococcal Pneumonia Overview Streptococcus pneumoniae, or pneumococcus, is a Gram-positive spherical bacteria,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Interferon Gamma-1b in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Interferon Gamma-1b in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon Gamma-1b in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Interferon Gamma-1B in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Interferon Gamma-1B in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon Gamma-1B in Metastatic Breast Cancer Drug Details: Human...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Interferon Gamma-1b in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Interferon Gamma-1b in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon Gamma-1b in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Consumer Insights
NewItaly Apparel Consumer Insights – Who Shops, What do they Shop, How do they Shop and Why do they Shop
This report provides detailed consumer insights into Italy's apparel market. It centers on consumer sentiment, categories purchased, channel usage, motivations for purchasing, purchase frequency and the most popular global brands. Many Italian consumers expect financial hardships to continue, with 49.0% and 30.9% anticipating that the economy and personal finances, respectively, will worsen over the next six months. As a result, 57.3% intend to reduce their retail expenditure, mainly by doing more price comparisons and shifting to cheaper brands. More Italian...
-
Product Insights
NewLikelihood of Approval Analysis for Simplexvirus (HSV) Infections
Overview How likely is it that the drugs in Simplexvirus (HSV) Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Simplexvirus (HSV) Infections Overview Herpes simplex virus (HSV) infections, also known...
-
Sector Analysis
United States (US) Retail Consumer Insights – Spending Intentions and Shopping Habits, 2024
US Retail Consumer Insights Report Overview More than 46% of consumers believe the economy will worsen over the next six months. Thus, consumers intend to cut back on retail goods and services. Furthermore, many US consumers stated that they are switching to economic brand alternatives to cope with cost pressures. This means that retailers must have a broad pricing architecture of brands stocked in-store to entice shoppers to trade up and down within the same retailer. The ‘US Retail Consumer...